Sakar Healthcare's Q4 FY 2025-26 Quarterly Results

Result Summary

• Sakar Healthcare Ltd reported a 0.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 41.4%.
• Its expenses for the quarter were down by 11.2% QoQ and up 20.4% YoY.
• The net profit increased 7.5% QoQ and increased 91.3% YoY.
• The earnings per share (EPS) of Sakar Healthcare Ltd stood at 4.96 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sakar Healthcare Ltd is a company that operates in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of pharmaceutical products. The company's portfolio includes a wide range of therapeutic segments such as anti-infectives, anti-diabetics, cardiovascular, gastrointestinal, and anti-inflammatory drugs, among others. This diverse product range positions Sakar Healthcare Ltd as a significant player in the healthcare sector, catering to both domestic and international markets. While specific recent developments or strategic initiatives were not provided, companies in this sector typically engage in activities such as research and development, expansion of manufacturing capabilities, and exploring new markets.

Revenue

During Q4 FY26, Sakar Healthcare Ltd reported a total income of ₹71.27 crores, marking a 0.6% increase from the previous quarter, Q3 FY26, where the total income was ₹70.85 crores. This quarterly growth is complemented by a significant year-over-year increase of 41.4% compared to Q4 FY25, when the total income stood at ₹50.42 crores. This substantial year-over-year growth indicates the company's expanding revenue base over the past year. The consistent increase in total income reflects the company's ability to generate higher sales or revenues over both the short and long term.

Profitability

In Q4 FY26, Sakar Healthcare Ltd achieved a Profit Before Tax (PBT) of ₹18.06 crores, an increase of 64.9% from ₹10.95 crores in Q3 FY26. Year-over-year, the PBT saw an impressive rise of 189.4% from ₹6.24 crores in Q4 FY25. The company's Profit After Tax (PAT) also increased to ₹11.02 crores in Q4 FY26, up by 7.5% from the previous quarter's ₹10.25 crores and up by 91.3% from ₹5.76 crores in Q4 FY25. This quarter exhibited a notable rise in tax expenditure, with tax payments jumping to ₹7.04 crores in Q4 FY26 from ₹0.70 crores in Q3 FY26 and ₹0.48 crores in Q4 FY25, reflecting a 905.7% and 1366.7% increase respectively.

Operating Metrics

The company's operating expenses showed a decrease in Q4 FY26, with total expenses amounting to ₹53.21 crores, compared to ₹59.90 crores in Q3 FY26, reflecting an 11.2% reduction quarter-over-quarter. Year-over-year, total expenses increased by 20.4% from ₹44.19 crores in Q4 FY25, indicating higher operational costs over the year. Earnings Per Share (EPS) for Q4 FY26 was reported at ₹4.96, showing an 8.1% rise from the previous quarter's EPS of ₹4.59 and an 87.2% increase from the EPS of ₹2.65 in Q4 FY25. These metrics illustrate the company's efficiency in managing operational costs while improving profitability per share over the analyzed periods.